Canine Influenza Vaccine, H3N8
Pharmaceutical Name
Canine Influenza Vaccine, H3N8 KILLED VIRUS
Features and Benefits
The First Vaccine to Protect Against Canine Influenza1
- Approved for the control of disease associated with canine influenza virus (CIV) infection
- Recommended for use in healthy dogs 6 weeks of age or older
- Contains killed (type A, subtype H3N8) virus combined with an adjuvant to enhance the immune response
Proven to significantly reduce the clinical signs, severity, and spread of canine influenza infection1
- Reduced the incidence and severity of coughing
- Decreased the overall clinical signs of disease including ocular and nasal discharge, coughing, sneezing, depression, and dyspnea
- Reduced the days and degree of viral shedding
- Demonstrated to protect against the formation and severity of lung lesions
Safety confirmed in a 746-dog field study1
- 100% reaction-free in this study
- Well tolerated in a multitude of breeds and ages
Easy to administer
- Subcutaneous injection
- Two 1-mL doses given 2 to 4 weeks apart
- Annual revaccination with one dose is recommended
Available in two convenient formulations
- 25 x 1 mL dose
- 5 x 10 mL dose (ideal for shelter environments)
Notice: This product license is conditional. As with all USDA conditionally licensed products, data submitted to the USDA supports a reasonable expectation of efficacy. Safety was established in trials involving more than 700 dogs.
Reference:
1. Intervet/Schering-Plough Animal Health, data on file.
For further information including complete directions and warnings, please see the PRODUCT LABEL.
